Short Interest in Generation Bio Co. (NASDAQ:GBIO) Grows By 16.3%

Generation Bio Co. (NASDAQ:GBIO) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 1,780,000 shares, an increase of 16.3% from the November 30th total of 1,530,000 shares. Based on an average daily volume of 223,300 shares, the short-interest ratio is presently 8.0 days. Approximately 4.2% of the company’s shares are sold short.

Hedge Funds Weigh In On Generation Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its holdings in shares of Generation Bio by 165.5% in the third quarter. Barclays PLC now owns 76,430 shares of the company’s stock valued at $189,000 after purchasing an additional 47,639 shares in the last quarter. State Street Corp boosted its position in Generation Bio by 1.2% during the 3rd quarter. State Street Corp now owns 992,188 shares of the company’s stock worth $2,451,000 after acquiring an additional 11,669 shares during the last quarter. Baker BROS. Advisors LP raised its holdings in shares of Generation Bio by 61.1% in the third quarter. Baker BROS. Advisors LP now owns 1,944,945 shares of the company’s stock valued at $4,804,000 after purchasing an additional 737,988 shares during the last quarter. FMR LLC lifted its position in shares of Generation Bio by 0.3% in the third quarter. FMR LLC now owns 5,320,266 shares of the company’s stock worth $13,141,000 after purchasing an additional 15,656 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Generation Bio by 2.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 423,299 shares of the company’s stock worth $1,046,000 after purchasing an additional 8,692 shares during the last quarter. 95.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on GBIO shares. Wedbush reissued an “outperform” rating and issued a $5.00 target price on shares of Generation Bio in a research note on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of Generation Bio in a research note on Wednesday, October 23rd.

Generation Bio Stock Performance

Shares of GBIO opened at $1.07 on Monday. The firm has a market cap of $71.47 million, a P/E ratio of -0.49 and a beta of 2.66. Generation Bio has a twelve month low of $0.75 and a twelve month high of $4.65. The firm’s 50 day moving average price is $1.62 and its two-hundred day moving average price is $2.28.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.